Xopenex Hfa
(levalbuterol)ApprovedSmall molecule
Xopenex Hfa is one of 14 small molecule programs targeting Status Asthmaticus. It is currently in Approved.
2
Indications
13
Total Trials
0
Active Trials
13
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in COPD
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimApproved
Daliresp
AstraZenecaApproved
Striverdi Respimat
Boehringer IngelheimApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marinol
Jazz PharmaceuticalsPhase 3
Xopenex Hfa
HHikma Pharmaceuticals LLC
Approved
Medrol
PfizerPreclinical
Dexpramipexole Dihydrochloride
AAreteia Therapeutics
Phase 2
DUPIXENT
RegeneronPreclinical
Symbicort
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Asthma7 trials
Show 4 more trials
Aerosolized Beta-Agonist Isomers in Asthma
Completed·—·Phase 4·NCT02170532·10 enrolled
Status Asthmaticus1 trial
Continuous Levalbuterol for Treatment of Status Asthmaticus in Children
Completed·—·Phase 4·NCT00124176·81 enrolled
Side Effects1 trial
Pediatric1 trial
Heart1 trial
Effect of Nebulized Bronchodilators on Heart Rate
Completed·—·Phase 4·NCT01151579·89 enrolled
2 more indications
Oxygen Consumption1 trial
Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults
Completed·—·N/A·NCT02802111·24 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 30, 2002
XOPENEX
NDA NDA020837
Mar 11, 2005
XOPENEX HFA
NDA NDA021730
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for levalbuterol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHikma Pharmaceuticals LLC